These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34855461)

  • 1. CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    Lamble AJ; Eidenschink Brodersen L; Alonzo TA; Wang J; Pardo L; Sung L; Cooper TM; Kolb EA; Aplenc R; Tasian SK; Loken MR; Meshinchi S
    J Clin Oncol; 2022 Jan; 40(3):252-261. PubMed ID: 34855461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.
    Bras AE; de Haas V; van Stigt A; Jongen-Lavrencic M; Beverloo HB; Te Marvelde JG; Zwaan CM; van Dongen JJM; Leusen JHW; van der Velden VHJ
    Cytometry B Clin Cytom; 2019 Mar; 96(2):134-142. PubMed ID: 30450744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
    Aref S; Azmy E; El Ghannam D; Haroun M; Ibrahim L; Sabry M
    Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic Significance of the Percentage of Blasts with CD34
    Xiang LL; Qiu GQ; Xie XB; Cen JN; Hu SY; Gu WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):61-65. PubMed ID: 28245376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic Value of CD123 in Acute Myeloid Leukemia Patients with Intermediate Risk in Normal Karyotype].
    Zhang Y; Liu RY; Wang SJ; Wang C; Zhang QT; He C; Xie XS; Wan DM; Jiang ZX; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1880-1884. PubMed ID: 33283714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.
    Das N; Gupta R; Gupta SK; Bakhshi S; Malhotra A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A; Sharma A; Kumar L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e673-e684. PubMed ID: 32561191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Loken MR; Gerbing RB; Ries RE; Aplenc R; Sung L; Raimondi SC; Hirsch BA; Kahwash SB; McKenney A; Kolb EA; Gamis AS; Meshinchi S
    Clin Cancer Res; 2017 Jul; 23(14):3649-3656. PubMed ID: 28108543
    [No Abstract]   [Full Text] [Related]  

  • 13. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.
    Loken MR; Alonzo TA; Pardo L; Gerbing RB; Raimondi SC; Hirsch BA; Ho PA; Franklin J; Cooper TM; Gamis AS; Meshinchi S
    Blood; 2012 Aug; 120(8):1581-8. PubMed ID: 22649108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
    Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
    Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression.
    Soare DS; Radu E; Dumitru I; Popov VM; Bumbea H; Vlădăreanu AM
    J Cell Mol Med; 2020 Jul; 24(13):7675-7679. PubMed ID: 32460405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts].
    Yue WQ; Tang GS; Liu M; Cheng H; Ding J; Wang T; Wang JM; Hu XX; Zhang WP; Chen L; Yang JM
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):876-882. PubMed ID: 29166741
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
    Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
    Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.
    Ehninger A; Kramer M; Röllig C; Thiede C; Bornhäuser M; von Bonin M; Wermke M; Feldmann A; Bachmann M; Ehninger G; Oelschlägel U
    Blood Cancer J; 2014 Jun; 4(6):e218. PubMed ID: 24927407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
    Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.